(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1 A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who…
Search results for: hospital
Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations
Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.
High Cost of Specialty Drugs Demands Action
Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.
Health Canada Approves Upadacitinib to Treat Adults with PsA
Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.
Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis
In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.
Grinding Away: An Overview of Progress in the Treatment & Management of Osteoarthritis
Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.
Insight into the Biosimilar Prescribing Habits of Rheumatologists
The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
Tofacitinib Promising for COVID-19 Pneumonia
(Reuters)—Pfizer Inc. said on June 16 its oral rheumatoid arthritis (RA) drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s main goal. Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published…
Polymyositis-Dermatomyositis Tied to Arrhythmias in Young, Middle-Aged Adults
(Reuters Health)—Young and middle-aged adults with polymyositis-dermatomyositis are more likely to have arrhythmias in general, and supraventricular arrhythmias in particular, than matched controls without these rare rheumatic conditions, a U.S. study suggests.1 Researchers examined retrospective data on adults hospitalized between 2016 and 2018, including 32,085 patients with polymyositis-dermatomyositis and 320,850 age-matched controls. Overall, both women…
Rituximab Seems Safe & Effective for Systemic Sclerosis
NEW YORK (Reuters Health)—Rituximab seemed to be a safe and effective treatment for systemic sclerosis (SSc) in a placebo-controlled validation trial in Japan.1 “A number of studies have examined B-cell depletion therapy for systemic sclerosis, and many of them have suggested that [this] is effective in treating systemic sclerosis,” Ayumi Yoshizaki, MD, tells Reuters Health…
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 323
- Next Page »